Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Esophageal cancer (EC) is one of the most common malignant tumors of the digestive tract in
human beings. Most cases of EC are initially diagnosed in an advanced stage of the disease.
Considering the lack of effective adjuvant therapies after surgery for locally advanced
esophageal squamous carcinoma. And with the encouraging preliminary results of PD-1
inhibitors in advanced esophageal squamous cell carcinoma (ESCC), postoperative adjuvant
immunotherapy for esophageal squamous carcinoma seems to be feasible. The main objective of
this study was the efficacy of postoperative adjuvant therapy with sintilimab in patients
with ESCC radically resected after neoadjuvant chemoimmunotherapy.